Cyclodextrin-based Pickering nanoemulsions containing amphotericin B: Part I. evaluation of oil/cyclodextrin and amphotericin B/cyclodextrin inclusion complexes

Maw, Phyo Darli; Jansook, Phatsawee

doi:10.1016/j.jddst.2022.103118

Cited by 5 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amphotericin B has low water solubility and therefore very poor bioavailability. The formation of inclusion complexes with CDs that interpose in a stable oil emulsion [ 38 ] has led to a significant increase in solubility with encouraging results in its pharmacokinetics and bioavailability.…”

Section: Cyclodextrins For Improved Drug Solubilitymentioning

confidence: 99%

“…Thus, the compartmentalization of isolated molecules in the cavities of cyclodextrins improves their stability by preventing the formation of dimers or protecting against hydrolysis under physiological pH conditions and, in some cases, increases bioavailability by slowing down metabolization. These effects have been reviewed [ 45 ] and the effects on the stability of penicillin antibiotics [ 46 ], the above-mentioned antifungal compound amphotericin B [ 38 , 47 ], and antidepressant drugs [ 48 ] have also been described.…”

Section: Cyclodextrins For Improved Drug Stabilitymentioning

confidence: 99%

See 1 more Smart Citation

Cyclodextrin Inclusion Complexes for Improved Drug Bioavailability and Activity: Synthetic and Analytical Aspects

Sarabia-Vallejo,

Caja,

Olives

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Many active pharmaceutical ingredients show low oral bioavailability due to factors such as poor solubility and physical and chemical instability. The formation of inclusion complexes with cyclodextrins, as well as cyclodextrin-based polymers, nanosponges, and nanofibers, is a valuable tool to improve the oral bioavailability of many drugs. The microencapsulation process modifies key properties of the included drugs including volatility, dissolution rate, bioavailability, and bioactivity. In this context, we present relevant examples of the stabilization of labile drugs through the encapsulation in cyclodextrins. The formation of inclusion complexes with drugs belonging to class IV in the biopharmaceutical classification system as an effective solution to increase their bioavailability is also discussed. The stabilization and improvement in nutraceuticals used as food supplements, which often have low intestinal absorption due to their poor solubility, is also considered. Cyclodextrin-based nanofibers, which are polymer-free and can be generated using environmentally friendly technologies, lead to dramatic bioavailability enhancements. The synthesis of chemically modified cyclodextrins, polymers, and nanosponges based on cyclodextrins is discussed. Analytical techniques that allow the characterization and verification of the formation of true inclusion complexes are also considered, taking into account the differences in the procedures for the formation of inclusion complexes in solution and in the solid state.

show abstract

Section: Cyclodextrins For Improved Drug Solubilitymentioning

confidence: 99%